The clinical studies performed regarding the impact of anti-Nogo-A and anti-LINGO-1 in MS-related patients did not yield the promise that was expected, but additional studies and information regarding Nogo-A and LINGO-1 will support the interpretation and planning of future clinical trials aiming for more successful outcomes in the treatment of neurodegenerative diseases like MS. Here, RTN4 is linked to neurodegenerative disease.